Sign in

Alzheimer disease

Current status: No cure yet

A brain disease that slowly harms memory and thinking, and the most common cause of dementia in older people. Medicines cannot stop it, but some can keep the symptoms from getting worse for a while. Most people who get it are over 65, and the risk rises with age: about 1 in 6 people over 80 has it or another type of dementia. The changes in the brain start many years before the first signs appear.

Read more about Alzheimer disease
Where research stands todayUpdated 18 Nov 2026

Trial-stage treatments and research studies you can joinOpen trials for referral

Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.

Filters

Country
City
Distance is calculated in your browser. Your city is not sent to us.
Type
Get notified of new trialsUnited Kingdom, all cities, all phases
Your ageShows only trials that take people your age.
Phase
  1. Trial-stage treatmentPhase 3Taking people
    Tests KarXT with KarX-EC for memory and thinking problems in Alzheimer's disease

    Tests KarXT with KarX-EC against a placebo in people with mild to moderate Alzheimer's.

    Birmingham, United KingdomAlso Edinburgh, Leeds, London, Manchester, Motherwell, Oxford, SheffieldAge 60 to 85
  2. Trial-stage treatmentPhase 1Taking people
    Tests ALN-APP, an injected drug, in early-onset Alzheimer's disease

    Tests the safety of ALN-APP, given by spinal injection, in adults with early-onset Alzheimer's.

    Sheffield, United KingdomAge 18+
  3. Trial-stage treatmentPhase 3
    Long-Term Safety Study of KarXT for Psychosis in Alzheimer's Disease

    Tests KarXT, a long-term safety study in people with Alzheimer's-related psychosis.

    Aberdeen, United KingdomAlso Chertsey, Ilford, Leeds, Motherwell, Preston, Sheffield, SouthYorkshire, Swindon, SwintonAge 55 to 90
  4. Trial-stage treatmentPhase 3Taking people
    Long-term study of KarXT and KarX-EC for agitation in Alzheimer's disease

    Tests KarXT and KarX-EC over time in people with Alzheimer's-related agitation.

    Cambridge, United KingdomAlso Chertsey, London, Motherwell, Preston, Redruth, Sheffield, Stafford, WolverhamptonAge 55 to 90
  5. Trial-stage treatmentPhase 2/3Taking people
    EXV-802 and EXV-801 for agitation in people with Alzheimer's disease dementia

    Tests EXV-802 and EXV-801 against placebo for agitation in Alzheimer's disease dementia.

    Aberdeen, United KingdomAlso EdinburghAge 55 to 90
  6. Trial-stage treatmentPhase 2Taking people
    Testing SAR448851, a daily pill, in people with early Alzheimer's disease

    Tests SAR448851 against placebo in people with early Alzheimer's disease.

    Bath, United KingdomAlso LondonAge 55 to 85
  7. Trial-stage treatmentPhase 3Taking people
    Trontinemab for people at risk of developing Alzheimer's disease who have no memory problems

    Tests trontinemab in people with early Alzheimer's disease changes but no symptoms.

    Aberdeen, United KingdomAlso Birmingham, Chertsey, Edinburgh, London, SouthamptonAge 55 to 80
  8. Trial-stage treatmentPhase 3Taking people
    Tests KarXT with KarX-EC for agitation in Alzheimer's disease

    Tests KarXT with KarX-EC against placebo in adults with Alzheimer's-related agitation.

    Cambridge, United KingdomAlso Chertsey, London, Motherwell, Preston, Redruth, Sheffield, Stafford, WolverhamptonAge 55 to 90
  9. Trial-stage treatmentPhase 1Taking people
    Tests LY3954068 safety in people with early Alzheimer's disease

    Tests LY3954068 injected into the spinal fluid in people with early Alzheimer's disease.

    London, United KingdomAlso Sheffield, SouthamptonAge 50 to 85
  10. Trial-stage treatmentPhase 2Taking people
    Testing MK-2214 in people with early Alzheimer's disease

    Tests whether MK-2214 slows tau buildup in adults with early Alzheimer's disease.

    Aberdeen, United KingdomAlso Bath, Birmingham, Edinburgh, London, Oxford, SouthamptonAge 50 to 85
  11. Trial-stage treatmentPhase 3
    Tests KarXT for psychosis in people with Alzheimer's disease

    Tests KarXT against placebo in people with Alzheimer's and psychosis.

    Aberdeen, United KingdomAlso Chertsey, Edinburgh, Ilford, Leeds, London, Motherwell, Preston, Sheffield, SouthYorkshire, …Age 55 to 90
  12. Trial-stage treatmentPhase 1Taking people
    Tests ALN-5288 injected into the spinal fluid for Alzheimer's disease

    Tests ALN-5288, given into the spinal fluid, in adults with Alzheimer's disease.

    Glasgow, United KingdomAlso London, Sheffield, SouthamptonAge 40 to 80
  13. Trial-stage treatmentPhase 1Taking people
    Safety of DNL921 in Healthy Adults and People With Alzheimer's Disease

    Tests the safety of DNL921 in healthy adults and people with Alzheimer's disease.

    Manchester, United KingdomAge 18 to 75
  14. Trial-stage treatmentPhase 3
    Tests KarXT for psychosis linked to Alzheimer's disease

    Tests KarXT against placebo in people with Alzheimer's-related psychosis to prevent relapse.

    Aberdeen, United KingdomAlso Motherwell, SwindonAge 55 to 90
  15. Trial-stage treatmentPhase 2/3Taking people
    Tests remternetug in people with an Alzheimer's-causing gene mutation

    Tests remternetug against placebo in adults with a gene mutation causing early Alzheimer's.

    London, United KingdomAge 18+
  16. Trial-stage treatmentPhase 2/3Taking people
    Tests remternetug in people at risk for early-onset familial Alzheimer disease

    Tests remternetug against placebo in adults with a genetic mutation causing Alzheimer disease.

    London, United KingdomAge 18+
  17. Trial-stage treatmentPhase 3Taking people
    Atomoxetine and metformin compared with placebo for symptomatic Alzheimer's disease

    Tests atomoxetine and metformin against placebo in people with symptomatic Alzheimer's disease.

    Cambridge, United KingdomAlso ChertseyAge 55+
  18. Trial-stage treatmentPhase 1/2Taking people
    Tests ACI-24.060 in early Alzheimer's disease and adults with Down syndrome

    Tests ACI-24.060 safety in early Alzheimer's and in adults with Down syndrome.

    Cambridge, United KingdomAlso Liverpool, London, Oxford, WarringtonAge 35 to 85
  19. Trial-stage treatmentPhase 1Taking people
    Testing DNL628 for Safety in People With Early Alzheimer's Disease

    Tests DNL628 against a placebo in adults with early Alzheimer's disease.

    London, United KingdomAge 18 to 75
  20. Trial-stage treatmentPhase 3Soon in United Kingdom
    Testing KarXT with KarX-EC for psychosis linked to Alzheimer's disease

    Tests KarXT with KarX-EC against placebo in adults with Alzheimer's-related psychosis.

    Chertsey, United KingdomAlso Crowborough, Exeter, London, Motherwell, Oxford, SheffieldAge 55 to 90

Search the publications

The results open on the publications page in a new tab, so this page stays as it is.

Lists with this disease filtered

Where treatment stands

In the EU, lecanemab was first approved in April 2025 and donanemab in September 2025.

Approved: 12

Officially approved for this disease in the EU, the US, Switzerland or France.

Human testing stage: 29

Being tested in people. Many treatments at this stage are never approved.

Animal testing stage: 5

Worked in animals in a study published in the last 12 months. Most treatments at this stage never reach people.

Lab research stage: 1

Worked on cells in the lab in a study published in the last 12 months. Most early ideas never reach people.

Support organisations

Patient organisations and helplines in United Kingdom, for you and your family.

Alzheimer disease organisations in United Kingdom

  • Dementia UK - Admiral Nurse Dementia Helpline

    Free helpline and webchat with specialist dementia (Admiral) nurses, virtual and face-to-face clinic appointments, BSL support, clinics for Black, African, Caribbean and Chinese communities.

  • Alzheimer Scotland

    24-hour freephone dementia helpline, Dementia Advisors (Mon-Fri 9-17, 0300 373 5774), Brain Health and Dementia Resource Centres with activities.

  • Alzheimer's Society

    Dementia Support Line (also Welsh line, interpreters, BSL), local support finder, online Dementia Support Forum, companionship service.

  • Dementia Carers Count

    Charity for family carers of people with dementia: free information, advice, courses and a Carer Support Line.

  • NHS – Dementia guide

    NHS public guide on dementia: symptoms, diagnosis, living well, care and support, financial and legal issues, information for carers.

General support in United Kingdom

  • NHS 111

    The NHS's free 24/7 urgent health advice service (phone 111 and NHS 111 online), with the nhs.uk health information website.

  • Samaritans

    UK charity offering free 24/7 confidential emotional support on 116 123 to anyone who is struggling, including people with suicidal thoughts.

  • Public Service Ombudsman (formerly Parliamentary and Health Service Ombudsman)

    Independent ombudsman making final decisions on complaints about the NHS in England and UK government departments not resolved locally.

International organisations

  • Alzheimer's Association

    Free 24/7 Helpline (interpreters for 200+ languages), care consultations with dementia experts, local chapters, Community Resource Finder, ALZConnected online community.

  • Alzheimer's Drug Discovery Foundation

    Funds the early work on new Alzheimer's medicines, in universities and companies.

  • BrightFocus Foundation

    US nonprofit that funds research and provides public information on Alzheimer's disease, macular degeneration and glaucoma.

  • Dementia Alliance International (DAI)

    Organisation for people with a dementia diagnosis: free online peer support groups, webinars, Brain Health Hub, resources for care partners.

Frontlight Community

Alzheimer disease community in United Kingdom

People living with Alzheimer disease and those close to them share what they went through. Posts are not medical advice: ask your doctor about your own treatment.

Offer tissue or data

There are three ways to help research move faster.

Give tissue or bloodA biobank stores your sample so many research teams can use it.See open programmes
Share your health dataA patient registry collects your health data, without your name, for research.How to join
Take part as a healthy volunteerStudies also need people without the disease, for comparison. Family and friends can help.Volunteer

Approved treatments

12 medicines are approved for Alzheimer disease in at least one of the places we checked. An approval in one place does not mean the medicine is offered or paid for where you live.

Checked on 18 Nov 2026 in the official lists of the US (FDA), the EU (European Commission and EMA) and Switzerland (Swissmedic), which we read every day. The lists of Japan (PMDA, approvals since April 2004), France (ANSM, medicines approved in France only) and Taiwan (TFDA) were checked on 11 Nov 2026. For Canada (Health Canada) and Singapore (HSA) we checked only whether a medicine is sold there, not what for. The French ratings are the opinions of the HAS Transparency Committee, from the French public medicines database (base de données publique des médicaments, newest opinion 10 Dec 2025). 4 uncertain matches are left out. Other countries' own approvals were not checked.

“Miracle cure” fact checker

Social media spreads misinformation. Paste here what you read, and we'll tell you whether there is scientific evidence behind it.

What you paste is checked with AI (Anthropic, USA) and is not stored. Please leave out names and other personal details.

Before you pay for anything, ask three things

  1. Is there a published study in people?
  2. Can I have the full price in writing?
  3. What does my doctor say?

“Cures” others already fact-checked

See all 2

About Alzheimer disease

Sources: NHS, MedlinePlus, Archives of Neurology

A brain disease that slowly harms memory and thinking, and the most common cause of dementia in older people. Medicines cannot stop it, but some can keep the symptoms from getting worse for a while. Most people who get it are over 65, and the risk rises with age: about 1 in 6 people over 80 has it or another type of dementia. The changes in the brain start many years before the first signs appear.

What is it?

Alzheimer's is the most common cause of dementia: a steady loss of memory, thinking and other mental abilities. Proteins build up in and around brain cells. One protein (amyloid) forms clumps around the cells, another (tau) forms tangles inside them. Over time parts of the brain shrink, usually the memory areas first. These changes begin many years before any signs. It is not a normal part of getting older.

Most people who get it are over 65, and the risk rises with age: about 1 in 14 people over 65 and 1 in 6 over 80 have Alzheimer's or another type of dementia. Genes usually raise the risk only a little. In a few families a single gene causes it, and then it is much more likely to be passed on.

The first signs

The signs come on slowly over several years and are sometimes taken for normal ageing.

  • forget recent conversations or events;
  • misplace things and forget the names of places and objects;
  • struggle to find the right word, or ask the same questions again and again;
  • find decisions harder and become more hesitant about trying new things;
  • feel anxious, agitated or confused at times.

How doctors find out

There is no simple, reliable test. The doctor checks your general health, may order blood tests and ask about your medicines to rule out other causes, and asks you to do some memory and thinking tasks. You may then be sent to a specialist, who may work at a memory clinic, for more tests such as a brain scan (CT or MRI). Finding out can take many months and several appointments.

Current treatment

Symptom medicines (e.g. donepezil) plus support

Will it get worse?

Yes. It is a progressive illness: the symptoms get worse slowly over several years. It gets worse slowly, at a different pace for each person. In the middle stage people usually need support with everyday living, such as help with eating, washing, getting dressed and using the toilet. In the severe stages they may need full-time care. People may live for several years after the signs begin, but this varies a lot. Alzheimer's shortens life, though many people with it die of something else.

Medicines: what helps, and what to watch for

Medicines cannot cure Alzheimer's, but some can ease the symptoms for a time. Donepezil, galantamine and rivastigmine raise acetylcholine, a brain chemical that helps nerve cells pass messages; they are used in the early and middle stages. Memantine works in a different way and is used when the disease is moderate or severe.

Good to know:

  • specialists, such as psychiatrists or neurologists, can prescribe these medicines; your family doctor may prescribe them on a specialist's advice;
  • feeling sick, being sick and losing your appetite can be side effects, and they usually get better after about 2 weeks;
  • memantine can cause headaches, dizziness and constipation, which usually pass;
  • for aggression or extreme distress, other ways of coping are tried first; antipsychotic medicines have serious side effects, so they should be used at the lowest dose for the shortest time possible.

Exercise and therapy help too

Some treatments without medicines can help memory, problem solving, mood and wellbeing:

  • cognitive stimulation therapy: group activities and exercises for memory and problem solving;
  • cognitive rehabilitation: working with a professional, such as an occupational therapist, and a relative or friend towards a personal goal, like using a mobile phone;
  • reminiscence and life story work: talking about the past with the help of photos, objects or music.

Exercise regularly, for example with a daily walk, gardening, tai chi or dancing.

Is there a cure?

Not yet. No treatment can stop the disease today.

See the 902 trials you can join

Median survival

About 3 to 8 years after diagnosis, depending on age at diagnosis

Measured in: Participants of the Baltimore Longitudinal Study of Aging older than 55, followed 1985–1999

The figures behind it

Baltimore Longitudinal Study of Aging (participants older than 55, followed 1985–1999): median survival 8.3 years when Alzheimer disease was diagnosed at age 65, down to 3.4 years when it was diagnosed at age 90; no significant difference between men and women.